PDE5 inhibitors ameliorate endothelial dysfunction, reduce inflammation, and improve diabetic cardiomyopathy and ischemia-reperfusion injury in type 2 diabetes.
Do PDE5 inhibitors improve cardiovascular complications in patients and animal models with type 2 diabetes?
PDE5 inhibitors show potential in ameliorating cardiovascular complications associated with type 2 diabetes by improving endothelial function and reducing inflammation.
Pharmacological inhibition of Phosphodiesterase type 5 (PDE5) proved its efficacy treating several pathological conditions, such as erectile dysfunction and pulmonary hypertension. Nowadays, its benefits on cardiovascular diseases are well documented, particularly in the treatment of type 2 diabetes (T2DM)-related cardiovascular complications. In this context, treatment of T2DM with PDE5 inhibitors, such as sildenafil, tadalafil or vardenafil ameliorates endothelial dysfunction both in patients and animal models through an augmented flow mediated dilation rate and an up-regulation of endothelial markers; it also reduces the inflammatory state by down-regulating inflammatory cytokines expression and improves diabetic cardiomyopathy and ischemia-reperfusion injury mainly through the activation of NO-cGMP-PKG pathway. The present review summarizes the state of art on PDE5 inhibition in the treatment of cardiovascular complications in T2DM.
Barbagallo et al. (Thu,) conducted a review in Type 2 diabetes-related cardiovascular complications. PDE5 inhibitors (sildenafil, tadalafil, vardenafil) was evaluated. PDE5 inhibitors ameliorate endothelial dysfunction, reduce inflammation, and improve diabetic cardiomyopathy and ischemia-reperfusion injury in type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: